Anti-neutrophil cytoplasmic antibody-associated vasculitis
Therapeutic area
Vascular Medicine
Rare disease
Yes
- Definition
- Group of systemic vasculitis with a strong association with anca. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Anti-neutrophil cytoplasmic antibody-associated vasculitis
- Therapeutic area
- Vascular Medicine
- anti-neutrophil cytoplasmic antibody-associated vasculitis
- AAV
- ANCA-associated vasculitis
- antineutrophil cytoplasmic antibody-associated vasculitis
- Disease mechanisms
- Inflammatory
- Severity
- Severe
- Cardiology
- Vascular Medicine
- MONDO ID
- MONDO:0015492
- Parent condition
- MONDO:0800113
Related records
Broader conditions (9)
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Human disease
- Inflammatory disease
- Necrotizing vasculitis
- Vascular disorder
- Vasculitis
Narrower conditions (3)
- Eosinophilic granulomatosis with polyangiitis
- Granulomatosis with polyangiitis
- Microscopic polyangiitis
Trials (153)
- (68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
- A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
- A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
- A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
- A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
- A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
- A Study of CCX168 in Japanese and Caucasian Healthy Adult Males
- A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
- A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases
- A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
- A Study of RD06-04 in Patients With Active Autoimmune Diseases
- A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants
- A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
- A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Approved drugs (1)
- Avacopan
Drugs in development (4)
- Ruxoprubart Phase 2
- Tarperprumig Phase 2
- Tominersen Phase 1
- Vilobelimab Phase 1
Other linked drugs (1)
- Lornoxicam